Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Sharon Mates currently holds 31,500 shares of Intra-Cellular Therapies, Inc. (ITCI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sharon Mates has been a net seller of ITCI stock. They have purchased $0 and sold $74.9M worth of shares.
Sharon Mates's most recent insider trade was on Jan 22, 2026, when they sold 31,500 shares at $0.00 per share.
Sharon Mates serves as Executive at Intra-Cellular Therapies, Inc. (ITCI). They have executed 163 insider transactions totaling $74.9M over their tenure at the company.
Sharon Mates holds the position of Executive at Intra-Cellular Therapies, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 11 years and currently hold a stake valued at $0.
Sharon Mates has shown a selling trading pattern, with $0 in total purchases and $74.9M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Sharon Mates was on Aug 21, 2024, when they sold $3.3M worth of ITCI shares. This transaction involved 44,134 shares at $75.40 per share.
Sharon Mates currently owns 31,500 shares of Intra-Cellular Therapies, Inc. (ITCI), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Sharon Mates's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Sharon Mates has 163 Form 4 filings on record as an insider at Intra-Cellular Therapies, Inc..
Set alerts for Sharon Mates and 40,000+ other insiders.